Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma

S I Tracy, M J Maurer, T E Witzig, M T Drake, S M Ansell, G S Nowakowski, C A Thompson, D J Inwards, P B Johnston, I N Micallef, C Allmer, W R Macon, G J Weiner, S L Slager, T M Habermann, B K Link, J R Cerhan, S I Tracy, M J Maurer, T E Witzig, M T Drake, S M Ansell, G S Nowakowski, C A Thompson, D J Inwards, P B Johnston, I N Micallef, C Allmer, W R Macon, G J Weiner, S L Slager, T M Habermann, B K Link, J R Cerhan

Abstract

We evaluated whether vitamin D insufficiency (VDI; 25(OH)D <20 ng/ml) was associated with adverse outcomes among follicular lymphoma (FL) patients using an observational prospective cohort study of 642 FL patients enrolled from 2002-2012. The median age at diagnosis was 60 years. At a median follow-up of 59 months, 297 patients (46%) had an event (progression, treatment failure), 78 had died and 42 (6.5%) had a lymphoma-related death. VDI was associated with inferior event-free survival (EFS) at 12 months (EFS12, odds ratio (OR)=2.05; 95% confidence interval (CI) 1.18-3.54), overall survival (OS, hazards ratio (HR)=2.35; 95%CI 1.37-4.02), and lymphoma-specific survival (LSS, HR=2.97; 95% CI 1.52-5.80) for the full cohort. Among patients treated with immunochemotherapy (IC), VDI was associated with inferior EFS12 (OR=3.00; 95% CI 1.26-7.13), OS (HR=2.86; 95% CI 1.39-5.85), and LSS (HR=2.96; 95% CI 1.29-6.79). For observed patients, VDI was associated with inferior OS (HR=2.85; 95% CI 1.20-6.76). For other therapies, VDI was associated with inferior OS (HR=3.06; 95% CI 1.01-9.24). Our work is the first to reveal an association of VDI with early clinical failure, and to demonstrate an association of VDI with adverse outcomes among patients who are observed or treated with therapies other than IC. Our findings suggest a potentially modifiable prognostic factor to address in patients with FL.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier curves for 25(OH)D insufficiency and OS for (a) all patients; (b) patients treated with IC; (c) patients observed without receiving therapy; and (d) patients receiving other therapies.
Figure 2
Figure 2
Kaplan–Meier curves for 25(OH)D insufficiency and EFS for (a) all patients; (b) patients treated with immunochemotherapy (IC); (c) patients observed without receiving therapy; and (d) patients receiving other therapies.

References

    1. Kahl BS, Yang DT. Follicular lymphoma: evolving therapeutic strategies. Blood 2016; 127: 2055–2063.
    1. Nooka AK, Nabhan C, Zhou X, Taylor MD, Byrtek M, Miller TP et al. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol 2013; 24: 441–448.
    1. Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol 2015; 33: 2516–2522.
    1. Maurer MJ, Bachy E, Ghesquieres H, Ansell SM, Nowakowski GS, Thompson CA et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol 2016; 91: 1096–1101.
    1. Drake MT, Maurer MJ, Link BK, Habermann TM, Ansell SM, Micallef IN et al. Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. J Clin Oncol 2010; 28: 4191–4198.
    1. Kelly JL, Salles G, Goldman B, Fisher RI, Brice P, Press O et al. Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation in SWOG and LYSA studies. J Clin Oncol 2015; 33: 1482–1490.
    1. Bittenbring JT, Neumann F, Altmann B, Achenbach M, Reichrath J, Ziepert M et al. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. J Clin Oncol 2014; 32: 3242–3248.
    1. Nabhan C, Zhou X, Day BM, Dawson K, Zelenetz AD, Friedberg JW et al. Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States. Am J Hematol 2016; 91: 770–775.
    1. Shanafelt TD, Drake MT, Maurer MJ, Allmer C, Rabe KG, Slager SL et al. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood 2011; 117: 1492–1498.
    1. Ng AC, Kumar SK, Rajkumar SV, Drake MT. Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. Am J Hematol 2009; 84: 397–400.
    1. Ng K, Meyerhardt JA, Wu K, Feskanich D, Hollis BW, Giovannucci EL et al. Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J Clin Oncol 2008; 26: 2984–2991.
    1. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009; 27: 3757–3763.
    1. Robsahm TE, Schwartz GG, Tretli S. The Inverse Relationship between 25-Hydroxyvitamin D and Cancer Survival: Discussion of Causation. Cancers 2013; 5: 1439–1455.
    1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. In: Bosman FT, Jaffe ES, Lakhani SR, Ohgaki H eds. International Agency for Research on Cancer: Lyon, 2008.
    1. Jaffe ES, Harris NL, Stein H, Vardiman JW eds. World Health Organization of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001.
    1. Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium Dietary Reference Intakes for Calcium and Vitamin D. National Academies Press (US): Washington (DC), 2011.
    1. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258–1265.
    1. Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med 2013; 369: 1991–2000.
    1. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004; 199: 1659–1669.
    1. Friedberg JW, Kahl BS, Leonard JP. The roadmap forward in follicular lymphoma: time for a precision approach. ASH Clin News 2015; 1: 29–30.
    1. Sfeir JG, Drake MT, LaPlant BR, Maurer MJ, Link BK, Berndt TJ et al. Validation of a vitamin D replacement strategy in vitamin D-insufficient patients with lymphoma or chronic lymphocytic leukemia. Blood Cancer J 2017; 7: e526.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe